NBIX insider transaction filings
NEUROCRINE BIOSCIENCES INC — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-15. Screen NBIX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 18 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 12 legs across 8 filings by 6 insiders — 45,479 shares, $7,945,005 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 44.
- Largest priced transaction: sale of 10,000 shares @ $179.60 ($1,796,014) by Lippoldt Darin, filed 2026-07-13.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Lippoldt Darin — Chief Legal Officer | 3 | — | 4 legs · 20,000 sh · $3,497,506 | 10 |
| Delaet Ingrid — Chief Regulatory Officer | 3 | — | 4 legs · 18,938 sh · $3,393,626 | 10 |
| ABERNETHY MATT — Chief Financial Officer | 1 | — | 1 leg · 2,311 sh · $363,285 | 2 |
| BENEVICH ERIC — Chief Commercial Officer | 2 | — | 1 leg · 2,154 sh · $333,030 | 4 |
| Norwalk Leslie V — Director | 1 | — | 1 leg · 1,250 sh · $227,508 | 2 |
| Boyer David W. — Chief Corp. Affairs Officer | 1 | — | 1 leg · 826 sh · $130,051 | 2 |
| Gano Kyle — Chief Executive Officer, Director | 1 | — | — | 4 |
| Onyia Jude — Chief Scientific Officer | 2 | — | — | 3 |
| Cooke Julie — Chief Human Resources Officer | 1 | — | — | 2 |
| GORMAN KEVIN CHARLES — Director | 1 | — | — | 2 |
+2 more insiders in the window, not shown — every filing appears in the table below.
Recent Form 4 filings — NEUROCRINE BIOSCIENCES INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-15 | 4 | BENEVICH ERIC — Chief Commercial Officer | Grant/award (A): 6,275 @ $0 · Tax withholding (F): 3,386 @ $156.22 | EDGAR |
| 2026-09-15 | 4 | Boyer David W. — Chief Corp. Affairs Officer | Grant/award (A): 3,587 @ $0 · Tax withholding (F): 1,936 @ $156.22 · Sale (S): 826 @ $157.45 | EDGAR |
| 2026-09-15 | 4 | Cooke Julie — Chief Human Resources Officer | Grant/award (A): 3,587 @ $0 · Tax withholding (F): 1,936 @ $156.22 | EDGAR |
| 2026-09-15 | 4 | Delaet Ingrid — Chief Regulatory Officer | Grant/award (A): 4,483 @ $0 · Tax withholding (F): 2,419 @ $156.22 | EDGAR |
| 2026-09-15 | 4 | Gano Kyle — Chief Executive Officer, Director | Grant/award (A): 6,275 @ $0 · Tax withholding (F): 3,386 @ $156.22 · Grant/award (A): 1,842 @ $0 · Tax withholding (F): 994 @ $156.22 | EDGAR |
| 2026-09-15 | 4 | GORMAN KEVIN CHARLES — Director | Grant/award (A): 14,343 @ $0 · Tax withholding (F): 7,839 @ $156.22 | EDGAR |
| 2026-09-15 | 4 | Keswani Sanjay Chandru — Chief Medical Officer | Grant/award (A): 3,914 @ $0 · Tax withholding (F): 2,112 @ $156.22 | EDGAR |
| 2026-09-15 | 4 | Lippoldt Darin — Chief Legal Officer | Grant/award (A): 4,483 @ $0 · Tax withholding (F): 2,419 @ $156.22 | EDGAR |
| 2026-09-15 | 4 | Onyia Jude — Chief Scientific Officer | Grant/award (A): 3,587 @ $0 · Tax withholding (F): 1,936 @ $156.22 | EDGAR |
| 2026-09-15 | 4 | ABERNETHY MATT — Chief Financial Officer | Grant/award (A): 5,020 @ $0 · Tax withholding (F): 2,709 @ $156.22 · Sale (S): 2,311 @ $157.20 | EDGAR |
| 2026-09-10 | 4 | BENEVICH ERIC — Chief Commercial Officer | Option exercise (M): 3,194 @ $43.24 · Sale (S): 2,154 @ $154.61 · Option exercise (M): 3,194 (derivative) @ $0 | EDGAR |
| 2026-09-03 | 4 | SHERWIN STEPHEN A — Director | Gift (G): 1,000 @ $0 | EDGAR |
| 2026-08-05 | 4 | Onyia Jude — Chief Scientific Officer | Gift (G): 2,409 @ $0 | EDGAR |
| 2026-07-30 | 4 | Norwalk Leslie V — Director | Sale (S): 1,250 @ $182.01 · Option exercise (M): 842 @ $139.43 · Option exercise (M): 842 (derivative) @ $0 | EDGAR |
| 2026-07-13 | 4 | Delaet Ingrid — Chief Regulatory Officer | Option exercise (M): 4,367 @ $106.02 · Sale (S): 4,367 @ $181.02 · Option exercise (M): 4,367 (derivative) @ $0 | EDGAR |
| 2026-07-13 | 4 | Lippoldt Darin — Chief Legal Officer | Option exercise (M): 10,000 @ $81.49 · Sale (S): 10,000 @ $179.60 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-07-09 | 4 | Delaet Ingrid — Chief Regulatory Officer | Option exercise (M): 3,401 @ $103.52 · Sale (S): 3,401 @ $178.57 · Option exercise (M): 2,737 @ $103.52 · Sale (S): 2,737 @ $178.54 · Option exercise (M): 8,433 @ $103.52 · Sale (S): 8,433 @ $178.72 · +3 more | EDGAR |
| 2026-06-30 | 4 | Lippoldt Darin — Chief Legal Officer | Option exercise (M): 200 @ $81.49 · Sale (S): 200 @ $169.56 · Option exercise (M): 8,110 @ $81.49 · Sale (S): 8,110 @ $170.03 · Option exercise (M): 1,690 @ $81.49 · Sale (S): 1,690 @ $170.81 · +3 more | EDGAR |
| 2026-06-09 | 4 | Onyia Jude — Chief Scientific Officer | Gift (G): 2,441 @ $0 | EDGAR |
| 2026-06-09 | 4 | SHERWIN STEPHEN A — Director | Option exercise (M): 15,000 @ $53.64 · Option exercise (M): 10,000 @ $79.79 · Sale (S): 7,883 @ $163.81 · Sale (S): 2,549 @ $164.44 · Sale (S): 6,896 @ $165.79 · Sale (S): 5,829 @ $166.56 · +3 more | EDGAR |
| 2026-06-08 | 4 | Norwalk Leslie V — Director | Sale (S): 1,250 @ $168.06 | EDGAR |
| 2026-06-04 | 4 | Keswani Sanjay Chandru — Chief Medical Officer | Option exercise (M): 3,212 @ $0 · Tax withholding (F): 1,733 @ $154.84 · Option exercise (M): 3,212 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Cooke Julie — Chief Human Resources Officer | Option exercise (M): 24,965 @ $81.49 · Sale (S): 14,214 @ $154.83 · Sale (S): 5,466 @ $155.46 · Sale (S): 4,216 @ $156.77 · Sale (S): 9,521 @ $157.62 · Sale (S): 3,520 @ $158.59 · +1 more | EDGAR |
| 2026-06-02 | 4 | Delaet Ingrid — Chief Regulatory Officer | Option exercise (M): 2,261 @ $79.02 · Sale (S): 2,261 @ $156.71 · Option exercise (M): 2,261 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Onyia Jude — Chief Scientific Officer | Option exercise (M): 11,000 @ $84.74 · Sale (S): 11,000 @ $160.25 · Option exercise (M): 11,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Onyia Jude — Chief Scientific Officer | Option exercise (M): 11,000 @ $84.74 · Sale (S): 11,000 @ $155.53 · Option exercise (M): 11,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Mercier Johanna — Director | Grant/award (A): 2,567 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Norwalk Leslie V — Director | Grant/award (A): 1,284 (derivative) @ $0 · Grant/award (A): 2,624 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Sharp Shalini — Director | Grant/award (A): 2,567 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | RASTETTER WILLIAM H — Director | Grant/award (A): 2,567 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | GORMAN KEVIN CHARLES — Director | Grant/award (A): 5,248 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | POON CHRISTINE A — Director | Grant/award (A): 2,567 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | POPS RICHARD F — Director | Grant/award (A): 2,567 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | LYONS GARY A — Director | Grant/award (A): 1,284 (derivative) @ $0 · Grant/award (A): 2,624 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | SHERWIN STEPHEN A — Director | Grant/award (A): 2,567 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | MORROW GEORGE J — Director | Grant/award (A): 2,567 (derivative) @ $0 | EDGAR |
| 2026-05-28 | 4 | Boyer David W. — Chief Corp. Affairs Officer | Sale (S): 3,888 @ $156.64 | EDGAR |
| 2026-05-21 | 4 | Mercier Johanna — Director | Option exercise (M): 3,318 @ $0 · Option exercise (M): 3,318 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Norwalk Leslie V — Director | Option exercise (M): 1,659 @ $0 · Option exercise (M): 1,659 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Sharp Shalini — Director | Option exercise (M): 1,659 @ $0 · Option exercise (M): 1,659 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | RASTETTER WILLIAM H — Director | Option exercise (M): 3,318 @ $0 · Option exercise (M): 3,318 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | GORMAN KEVIN CHARLES — Director | Option exercise (M): 205,088 @ $43.24 · Sale (S): 245,088 @ $154.33 · Option exercise (M): 205,088 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | POON CHRISTINE A — Director | Option exercise (M): 3,318 @ $0 · Option exercise (M): 3,318 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | POPS RICHARD F — Director | Option exercise (M): 3,318 @ $0 · Option exercise (M): 3,318 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | LYONS GARY A — Director | Option exercise (M): 1,659 @ $0 · Option exercise (M): 1,659 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | SHERWIN STEPHEN A — Director | Option exercise (M): 3,318 @ $0 · Option exercise (M): 3,318 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | MORROW GEORGE J — Director | Option exercise (M): 3,318 @ $0 · Option exercise (M): 3,318 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | POPS RICHARD F — Director | Option exercise (M): 15,000 @ $47.89 · Sale (S): 15,000 @ $157.65 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | Norwalk Leslie V — Director | Sale (S): 3,810 @ $155.01 | EDGAR |
| 2026-03-05 | 4 | ABERNETHY MATT — Chief Financial Officer | Gift (G): 2,249 @ $0 | EDGAR |
Recent 8-K events — NEUROCRINE BIOSCIENCES INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-31 | 8-K/A | 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-06 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-24 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NBIX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →